Company Filing History:
Years Active: 2022-2023
Title: Christopher Egan: Innovator in Nucleic Acid Detection
Introduction
Christopher Egan is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of nucleic acid detection, holding 2 patents that showcase his innovative methods and techniques. His work is instrumental in advancing the capabilities of molecular diagnostics.
Latest Patents
Egan's latest patents focus on methods for the detection of nucleic acids of defined sequence. The first patent describes a nucleic acid detection method that employs nicking agents, polymerase, and oligonucleotide probes to produce probe fragments in the presence of a target nucleic acid. The second patent also relates to nucleic acid detection methods, utilizing nicking agents and a sequential series of oligonucleotide probes to achieve similar results. These inventions are crucial for enhancing the accuracy and efficiency of nucleic acid detection.
Career Highlights
Christopher Egan is associated with Sense Biodetection Limited, where he applies his expertise in developing innovative solutions for nucleic acid detection. His work at the company reflects his commitment to advancing scientific research and improving diagnostic methods.
Collaborations
Egan collaborates with notable colleagues, including Henry John Lamble and David Lloyd. Their combined efforts contribute to the development of cutting-edge technologies in the field of molecular diagnostics.
Conclusion
Christopher Egan's contributions to nucleic acid detection are significant and impactful. His patents and work at Sense Biodetection Limited highlight his role as an innovator in the field. Egan's dedication to advancing molecular diagnostics continues to influence the industry positively.